Drug Profile
Research programme: protein kinase C theta inhibitors - Pfizer
Latest Information Update: 20 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Small molecules
- Mechanism of Action Protein kinase C theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 20 Sep 2011 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 26 Mar 2009 Pharmacodynamics data from a preclinical trial in Autoimmune disorders presented at the 237th American Chemical Society National Meeting (237th-ACS-2009)